CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,660 enrolled
Drug / intervention
MenACYW conjugate vaccine +5 morebiological
Likely dose
MenACYW conjugate vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03547271
NCT03547271Phase 3Completed

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Sanofi Pasteur, a Sanofi Company·interventional·Posted Jun 6, 2018·Updated Mar 3, 2025

In Brief

A Phase 3 clinical trial evaluating MenACYW conjugate vaccine, Meningococcal group A, C, W-135, and Y conjugate vaccine, and 4 other interventions for Meningococcal Infections. Completed, enrolled 1,660 participants across 33 sites in 7 countries.

Detailed Summary

Primary objective: This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b \[DTaP-IPV-HB-Hib vaccine\]) to infants and toddlers 6 weeks to 18 months old Secondary objectives: This study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old. \- This study aimed to describe the Ab responses against meningococcal groups A, C, Y, and W and the antigens of the routine pediatric vaccines administered in the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, Finland, Italy, Poland, Romania, Spain, Sweden
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 6, 2018
Enrollment StartDec 14, 2018
Primary CompletionMay 17, 2023
Study CompletionMay 24, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 8.1 years ago

Interventions

MenACYW conjugate vaccinebiological

Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular

Meningococcal group A, C, W-135, and Y conjugate vaccinebiological

Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular

DTaP-IPV-HB-Hib vaccinebiological

Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine

Pneumococcal vaccine (13-valent)biological

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

Pneumococcal vaccine (10-valent)biological

Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)

MMR vaccinebiological

Measles, mumps, and rubella vaccine